Please login to the form below

Not currently logged in
Email:
Password:

Penn launches US operation

UK-based Penn Pharmaceutical Services has launched a company in North America, in the next phase of its growth in the region after a recent GBP 67m (USD 139.5m) management buyout.

UK-based Penn Pharmaceutical Services has launched a company in North America, in the next phase of its growth in the region after a recent GBP 67m (USD 139.5m) management buyout.

Penn, which provides integrated pharmaceutical outsourcing services, has set up Penn Pharmaceutical Services US in Philadelphia. The company has hired Paul Wituschek as director of business development to head up the new business arm.

Penn employs more than 200 people and operates from a base in Wales. It provides a variety of technical services to the pharmaceutical industry through three core divisions.

Wituschek has over 20 years' experience in executive level sales, marketing and management experience in private sector business. He has also worked in pharmaceutical, biotechnology, healthcare, insurance and publishing industries, managing teams globally throughout North America, the UK and the EU.

Most recently, Wituschek was global sales director for the Pharma Solutions Business Unit of US-based Wolters Kluwer Health, where he had profit and loss responsibility for the Global Business Intelligence portfolio and led his teams to record sales and revenue growth.

Penn Pharmaceutical's CEO, Peter George, said: "Development of our North American office is critical to maintain our planned growth rate of over 20 per cent and Paul has all of the assets required to drive the business forward and increase our presence there. As a member of the executive management team, Paul will ensure that future developments take account of the North American market needs."

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Peter Howarth
Exploring the potential of eosinophils
GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...
white house
Eliminating pharmaceutical rebates, is this déjà vu?
By Andrew Parece and Matthew Majewski...
Patients are ready to embrace decentralised clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...

Infographics